Entero Therapeutics (ENTO) Stock Price, News & Analysis

Company Overview

Entero Therapeutics, Inc. (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations.

Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.

Key Stats

• Today's Range: $2.98 to $3.70
• 50-Day Range: $1.09 to $3.15
• 52-Week Range: $0.92 to $3.70
• Volume: 257,724 shs
• Average Volume: 884,376 shs
• Market Capitalization: $5.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENTO Stock Analysis - Frequently Asked Questions

How have ENTO shares performed this year?

Entero Therapeutics' stock was trading at $1.8660 at the beginning of 2025. Since then, ENTO shares have increased by 88.9% and is now trading at $3.5250.

How were Entero Therapeutics' earnings last quarter?

Entero Therapeutics, Inc. (NASDAQ:ENTO) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.42) earnings per share (EPS) for the quarter.

When did Entero Therapeutics' stock split?

Entero Therapeutics shares reverse split on the morning of Monday, August 18th 2025.A 1-3 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

How do I buy shares of Entero Therapeutics?

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Entero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include CDT Equity (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTO
• Previous Symbol: NASDAQ:ENTO
• CIK: 1604191
• Web: www.enterothera.com
• Phone: 561-589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,063.82%
• Return on Assets: -17.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.81
• Quick Ratio: 2.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.45) per share
• Price / Book: -1.29

Miscellaneous

• Outstanding Shares: 1,590,000
• Free Float: 1,576,000
• Market Cap: $5.01 million
• Optionable: N/A
• Beta: 0.88